Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Anavex Life Sciences Corp
0HFRCurrent price
5.1 USD
+0.032 USD (+0.64%)
Last closed
5.01 USD
Company
www.anavex.com
ISIN
US0327973006
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
436 696 864 USD
Yield for 12 month
-33.03 %
1Y
3Y
5Y
10Y
15Y
0HFR
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. Address: 630 5th Avenue, New York, NY, United States, 10111
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
35.47 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures 0HFR
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.43 %
PEG Ratio
–
Return On Equity TTM
-30.03 %
Wall Street Target Price
35.47 USD
Revenue TTM
–
Book Value
1.53 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.51 USD
Diluted Eps TTM
-0.51 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 0HFR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0HFR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:4
Payout Ratio
–
Last Split Date
07.10.2015
Dividend Date
–
Stock Valuation 0HFR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-5.5379
Price Book MRQ
3.3616
Financials 0HFR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0HFR
For 52 weeks
3.25 USD
10.45 USD
50 Day MA
5.81 USD
Shares Short Prior Month
19 883 543
200 Day MA
5.54 USD
Short Ratio
15.75
Shares Short
19 746 435
Short Percent
24.02 %
BeatStart